LEIDEN, Netherlands, January 28, 2025 / Biotech Newswire / -- MIMETAS, a global leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts at SLAS 2025 as a key addition to MIMETAS’ service portfolio.
OrganoPlate UF addresses challenges in traditional flow systems by enabling physiologically accurate tissue models that replicate natural biological conditions. With unidirectional, gravity-driven flow, this system eliminates the need for external pumps, simplifying operation while enhancing model accuracy. Supporting up to 512 chips in a single setup, the technology is ideal for rigorous scientific studies and large-scale screening, accelerating research without compromising biological relevance.
Key Features of OrganoPlate UF Technology:
- Unidirectional flow: Improves modeling of vasculature for studies in cardiovascular, oncological, and immunological research.
- Pump-free, gravity-driven design: Simplifies operations while mimicking natural flow conditions.
- Scalable and compatible: Operates seamlessly with standard liquid handling and imaging equipment, enabling high-throughput analysis of hundreds or thousands of tissue models.
- Stable, long-term culture: Supports extended culture of complex tissues for chronic disease and therapeutic studies.
Driving Innovation in Drug Discovery
“The MIMETAS OrganoPlate has led the field in microphysiological cell culture for over 12 years,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we’ve achieved unidirectional flow that mimics blood circulation while maintaining the ease of use, compatibility, and throughput that make our technology exceptional.”
OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models and is used to study immunological, cardiovascular, and metabolic diseases, as well as cancer. This platform is now available as part of MIMETAS’ service offerings.
For high resolution please click the image.
About MIMETAS
MIMETAS (Leiden, Netherlands) is a global leader in human-relevant disease models for drug discovery and development. Its proprietary OrganoPlate® platform powers a broad range of physiologically comprehensive disease assays, deployed in partnership with top pharmaceutical companies worldwide. Founded in 2013, MIMETAS operates globally across Europe, Asia, and the USA.
Contact
MIMETAS
Mieke Doornbos, VP Sales & Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Research; Laboratories; Automation; Models, Biological; Biological Assay; High-Throughput Screening Assays; Lab-On-A-Chip Devices; Automation; Organoids; Technology; Drug Discovery; Drug Industry; Biotechnology; Netherlands; MIMETAS; OrganoPlate UniFlow (UF); Unidirectional flow; Gravity-driven flow system; Disease research; SLAS 2025; Tissue models; Cardiovascular research; Oncological research; Immunological research; High-throughput analysis; Long-term culture; Chronic disease studies; Therapeutic studies; Microphysiological cell culture; Liver models; Lung models; Brain models; Vasculature models; Tumor models; Cancer research; Drug development; OrganoPlate platform; USA
Source: Biotech Newswire